Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ascendis Pharma A/S T.ASND


Primary Symbol: ASND

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).


NDAQ:ASND - Post by User

Post by 101724on Jun 18, 2024 6:25pm
187 Views
Post# 36094992

Nothing ever adds up with Extension Resources

Nothing ever adds up with Extension ResourcesWith a little over 200,000 shares voted "NO" on everything that was on the proxy, somehow about 75,000 "NO" shares are missing from the count. And that's assuming I was the only "NO" votes. Nice to see Brennan's "NO" votes total increasing. One other note. You had a shareholders' meeting and didn't give any insight on the direction of building a mine? Clown show.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities